Tracheal allograft stable after immunosuppressive therapy

Tracheal allograft stable after immunosuppressive therapy

(HealthDay)—A composite-tissue tracheal allograft appears to have retained its structural integrity after the withdrawal of immunosuppressive therapy, according to a letter to the editor published in the April 17 issue of the New England Journal of Medicine.

Pierre R. Delaere, M.D., Ph.D., from the University Hospital Leuven in Belgium, and colleagues have performed tracheal allografts in five (four patients with long-segment stenosis and one patient with a low-grade chondrosarcoma). In the patient with recurrent tracheal chondrosarcoma, rejection was visualized in situ following withdrawal of . The authors report on the healing mechanisms responsible for the survival of the allograft after immunologic rejection of the donor tissue.

The researchers write that an allograft was placed in this patient's forearm for three months, during which time, the donor respiratory epithelium was revascularized and an autograft of recipient buccal mucosa was introduced in the midportion of the allograft. Following resections of the patient's tracheal tumor, the allograft was moved to its correct anatomical position with an intact blood supply.

"Two years after transplantation, the allograft was stable and functional, and the patient reported that he was satisfied with the result," the authors write.


Explore further

Leading surgeons warn against media hype about tracheal regeneration

More information: Full Text
Journal information: New England Journal of Medicine

Copyright © 2014 HealthDay. All rights reserved.

Citation: Tracheal allograft stable after immunosuppressive therapy (2014, April 17) retrieved 19 September 2019 from https://medicalxpress.com/news/2014-04-tracheal-allograft-stable-immunosuppressive-therapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more